Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
Recruiting
Observational Study
Childhood ALL
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- Up to 18
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- French Africa Pediatric Oncology Group · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2
\-
Exclusion Criteria:
ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21
Contacts